TFF Pharmaceuticals Engages Outcome Capital As a Strategic Advisor for Evaluating Partnership and Licensing Opportunities

"In recent months, TFF Pharmaceuticals has made extraordinary progress in demonstrating how its leading formulation technology can be applied to generate innovative clinical-stage products with the potential to improve upon the current standard of care," said Oded Ben-Joseph, Ph.D., MBA, Managing Partner of Outcome Capital. "We look forward to identifying and evaluating opportunities to realize the full potential value of TFF Pharmaceutical's exciting Phase 2 assets." About TFF TAC TFF TAC is an inhaled dry ...